Filana Therapeutics’ FDA clinical hold on simufilam was lifted, clearing its planned proof-of-concept study and putting patient screening on track for the first quarter of 2027. The study is intended to produce data that guide simufilam’s development in TSC-related epilepsy and inform future research involving younger patients.
Key Highlights
- The planned proof-of-concept study will examine seizure frequency, intensity, duration, nighttime seizures and sleep-related outcomes.
- FDA lifted the clinical hold on Filana’s IND for simufilam.
- Preparation for the TSC-related epilepsy proof-of-concept study included appointing a CRO, selecting trial locations and securing investigational drug supply.
- The trial will assess safety, tolerability, pharmacokinetics and seizure- and sleep-related outcomes.
Filana Therapeutics, Inc. (NASDAQ: FLNA) is a biotechnology company. The FDA has lifted its clinical hold on Filana’s investigational new drug application for simufilam, allowing the planned proof-of-concept study in TSC-related epilepsy to advance.
Simufilam Study Moves Toward Patient Enrollment
Filana completed several preparation steps while the hold was in place. Those efforts included appointing a clinical research organization, selecting trial locations and recruiting potential investigators, while investigational drug Supply has been secured. Participants completing the blinded treatment period may take part in an extension study.
Data Intended to Guide Future Development
The trial is designed to examine safety, tolerability and pharmacokinetics, alongside seizure frequency, intensity, duration, nighttime seizures and sleep-related outcomes. Filana expects the resulting data to help determine the development route for simufilam in TSC-related epilepsy. The findings are also intended to inform the design of later studies involving younger patient populations.
FAQs
Q: What did the FDA change for Filana Therapeutics’ simufilam program?
A: The FDA lifted the clinical hold on Filana Therapeutics’ investigational new drug application. The decision allows the planned simufilam study in TSC-related epilepsy to proceed.
Q: When is Filana Therapeutics expected to begin patient screening?
A: Filana Therapeutics is targeting 2027 to begin patient screening. The article does not provide a more specific date.
Q: What will Filana’s simufilam study measure?
A: The study will assess safety, tolerability and pharmacokinetics. It will also track seizure frequency, intensity, duration, nighttime seizures and sleep-related outcomes.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.